ABX TECHNOLOGY:

Biocompatible, cushioning, & lubricating

​

Tissue-protecting and function-restoring biomedical polymers

​

Our first product candidate will relieve pain and restore mobility to sufferers of osteoarthritis.

OUR TEAM

BENJAMIN COOPER

R&D, operations, biomedical engineering

YIANNIS MONOVOUKAS

Business, management, product development

MARK GRINSTAFF

Translational research, polymer & materials science

ABOUT

Spun out of Boston University in 2016, Articulate Biosciences is a preclinical stage medical device company. We are seeking rapid growth to expand our team and develop a portfolio of products for several key indications in orthopedics and soft tissue repair.

​

Using our patented ABX platform technology, our mission is to deliver long-lasting pain relief and restoration of mobility to sufferers of osteoarthritis. Through deep understanding of patient and clinician needs, combined with innovative breakthroughs in medical device technology, Articulate Biosciences strives to bring back quality of life by eliminating chronic joint pain

NEWS

June 2018

AWARDED $225,000 PHASE I SBIR GRANT (NSF)

March 2018

ARTICULATE SELECTED AS AUDIENCE FAVORITE, MASS INNOVATION NIGHT

January 2018

ARTICULATE SELECTED AS A JLABS COMPANY

January 2018

UNITED STATES PATENT COVERING ABX TECHNOLOGY IS ISSUED

September 2017

AWARDED $200,000 PHASE I SBIR GRANT (NIH)

July 2017

PARTICIPANT IN THE NSF I-CORPS PROGRAM

April 2017

WINNER IN THE MA MEDICAL DEVICE DEVELOPMENT CENTER (M2D2) $100K CHALLENGE

July 2016

PARTICIPANT IN THE BOSTON UNIVERSITY QUESTROM SCHOOL OF BUSINESS SUMMER ACCELERATOR

January 2016

ARTICULATE BIOSCIENCES IS FOUNDED

July 2015

PROF. MARK GRINSTAFF AWARDED $225,000 BOSTON UNIVERSITY & COULTER FOUNDATION GRANT